Details of the Drug Combinations

General Information of This Drug (ID: DMF3MV1)

Drug Name
GDC-0980/RG7422   DMF3MV1
Synonyms
Apitolisib; 1032754-93-0; GDC-0980; GDC0980; RG7422; (S)-1-(4-((2-(2-aminopyrimidin-5-yl)-7-methyl-4-morpholinothieno[3,2-d]pyrimidin-6-yl)methyl)piperazin-1-yl)-2-hydroxypropan-1-one; UNII-1C854K1MIJ; GDC-0980 (RG7422); Apitolisib (GDC-0980, RG7422); 1C854K1MIJ; CHEMBL1922094; RG-7422; (2s)-1-(4-{[2-(2-Aminopyrimidin-5-Yl)-7-Methyl-4-(Morpholin-4-Yl)thieno[3,2-D]pyrimidin-6-Yl]methyl}piperazin-1-Yl)-2-Hydroxypropan-1-One; J-502360; C23H30N8O3S
Indication
Disease Entry ICD 11 Status REF
Non-hodgkin lymphoma 2B33.5 Phase 2 [1]
Solid tumour/cancer 2A00-2F9Z Phase 1 [2]
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL

List of Combinatorial Drugs (CBD) Containing This Drug

36 Investigative Drug Combination(s) Consisting of This drug
Normalized Drug Combination Synergy Score
Synergy scores were normalized using Min-Max Scaling to facilitate visual comparisons.
DrugCom Name DrugCom ID Component Drug Indication REF
ABT-263 + GDC-0980/RG7422 DCXBUDT ABT-263 Glioblastoma (Cell Line: JHH-136) [3]
AZD8055 + GDC-0980/RG7422 DCHN5V2 AZD8055 Glioblastoma (Cell Line: JHH-136) [4]
Bardoxolone methyl + GDC-0980/RG7422 DC6SO7B Bardoxolone methyl Glioblastoma (Cell Line: JHH-136) [4]
CA4P + GDC-0980/RG7422 DC35FTU CA4P Diffuse intrinsic pontine glioma (Cell Line: SU-DIPG-XIII) [4]
CA4P + GDC-0980/RG7422 DC3H74G CA4P Glioblastoma (Cell Line: JHH-136) [4]
CUDC-101 + GDC-0980/RG7422 DCNDBWB CUDC-101 Diffuse intrinsic pontine glioma (Cell Line: SU-DIPG-XIII) [4]
Fenretinide + GDC-0980/RG7422 DCYVERR Fenretinide Glioblastoma (Cell Line: JHH-136) [4]
GDC-0980/RG7422 + Ruxolitinib DCKCEHG Ruxolitinib T-cell leukemia/lymphoma (Cell Line: ED-40515) [4]
GDC-0980/RG7422 + PD-0325901 DCZJMSK PD-0325901 Diffuse intrinsic pontine glioma (Cell Line: SU-DIPG-XIII) [4]
GDC-0980/RG7422 + Trametinib DCLB79G Trametinib Glioblastoma (Cell Line: JHH-136) [4]
GDC-0980/RG7422 + Panobinostat DCD03O6 Panobinostat Diffuse intrinsic pontine glioma (Cell Line: DIPG25) [4]
GDC-0980/RG7422 + Cantharidin DCFGIFJ Cantharidin Diffuse intrinsic pontine glioma (Cell Line: SU-DIPG-XIII) [4]
GDC-0980/RG7422 + RAF265 DCY8OJB RAF265 Diffuse intrinsic pontine glioma (Cell Line: SU-DIPG-XIII) [4]
GDC-0980/RG7422 + THAPSIGARGIN DC3EMQ0 THAPSIGARGIN Diffuse intrinsic pontine glioma (Cell Line: SU-DIPG-XIII) [4]
GDC-0980/RG7422 + Mifepristone DC9504L Mifepristone Diffuse intrinsic pontine glioma (Cell Line: SU-DIPG-XIII) [4]
GDC-0980/RG7422 + SNDX-275 DCCI3LP SNDX-275 Diffuse intrinsic pontine glioma (Cell Line: SU-DIPG-XIII) [4]
GDC-0980/RG7422 + GSK618334 DCXSU5Q GSK618334 Diffuse intrinsic pontine glioma (Cell Line: SU-DIPG-XIII) [4]
GDC-0980/RG7422 + Tamoxifen DCFQZYZ Tamoxifen Diffuse intrinsic pontine glioma (Cell Line: SU-DIPG-XIII) [4]
GDC-0980/RG7422 + Ciclopirox DCS5CFG Ciclopirox Diffuse intrinsic pontine glioma (Cell Line: SU-DIPG-XIII) [4]
GDC-0980/RG7422 + ABT-263 DCU9FZP ABT-263 Diffuse intrinsic pontine glioma (Cell Line: SU-DIPG-XIII) [4]
GDC-0980/RG7422 + BIIB-021 DCV6540 BIIB-021 Diffuse intrinsic pontine glioma (Cell Line: SU-DIPG-XIII) [4]
GDC-0980/RG7422 + Auranofin DC2FVKV Auranofin Diffuse intrinsic pontine glioma (Cell Line: SU-DIPG-XIII) [4]
GDC-0980/RG7422 + Ruxolitinib DC3M1T3 Ruxolitinib Hodgkin lymphoma (Cell Line: L-1236) [3]
GDC-0980/RG7422 + Trametinib DCFTAZX Trametinib Embryonal rhabdomyosarcoma (Cell Line: Rh36) [3]
GDC-0980/RG7422 + Trametinib DCHE4QO Trametinib Embryonal rhabdomyosarcoma (Cell Line: CTR) [3]
GDC-0980/RG7422 + Trametinib DCKCOWC Trametinib Embryonal rhabdomyosarcoma (Cell Line: RD) [3]
GDC-0980/RG7422 + Cotellic DCTJOWS Cotellic Embryonal rhabdomyosarcoma (Cell Line: Rh36) [3]
GDC-0980/RG7422 + Cotellic DCHLHA7 Cotellic Embryonal rhabdomyosarcoma (Cell Line: CTR) [3]
GDC-0980/RG7422 + Cotellic DCBEPIW Cotellic Embryonal rhabdomyosarcoma (Cell Line: RD) [3]
GDC0941 + GDC-0980/RG7422 DCX8G0T GDC0941 Glioblastoma (Cell Line: JHH-136) [4]
Piperaquine + GDC-0980/RG7422 DC6JRID Piperaquine Glioblastoma (Cell Line: JHH-136) [4]
RTB101 + GDC-0980/RG7422 DC7CCIO RTB101 Diffuse intrinsic pontine glioma (Cell Line: SU-DIPG-XIII) [4]
SCH 727965 + GDC-0980/RG7422 DC6SUCL SCH 727965 Diffuse intrinsic pontine glioma (Cell Line: SU-DIPG-XIII) [4]
TAK-733 + GDC-0980/RG7422 DCOHG9P TAK-733 Glioblastoma (Cell Line: JHH-136) [4]
Topetecan + GDC-0980/RG7422 DC7HYUH Topetecan Glioblastoma (Cell Line: JHH-136) [4]
Trametinib + GDC-0980/RG7422 DC4JR8F Trametinib Diffuse intrinsic pontine glioma (Cell Line: SU-DIPG-XIII) [3]
------------------------------------------------------------------------------------
⏷ Show the Full List of 36 DrugCom(s)
2 Clinical Trial Drug Combination(s) Consisting of This drug
DrugCom Name DrugCom ID Component Drug Indication REF
Fulvestrant + GDC-0980/RG7422 DCKNLWO Fulvestrant Breast Cancer [5]
GDC-0980/RG7422 + Capecitabine DCROML6 Capecitabine Solid Cancers [6]
------------------------------------------------------------------------------------

References

1 Clinical pipeline report, company report or official report of Roche.
2 Clinical pipeline report, company report or official report of Genentech (2011).
3 Loss of function mutations in VARS encoding cytoplasmic valyl-tRNA synthetase cause microcephaly, seizures, and progressive cerebral atrophy.Hum Genet. 2018 Apr;137(4):293-303. doi: 10.1007/s00439-018-1882-3. Epub 2018 Apr 24.
4 Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.
5 ClinicalTrials.gov (NCT01437566) Study of GDC-0941 or GDC-0980 With Fulvestrant Versus Fulvestrant in Advanced or Metastatic Breast Cancer in Participants Resistant to Aromatase Inhibitor Therapy
6 ClinicalTrials.gov (NCT01332604) GDC-0980 in Combination With a Fluoropyrimidine, Oxaliplatin, and Bevacizumab in Patients With Advanced Solid Tumors